Sex-specific differences in the severity of pulmonary hypoplasia in experimental congenital diaphragmatic hernia and implications for extracellular vesicle-based therapy
Topic overview
Study examines sex-specific differences in lung underdevelopment caused by congenital diaphragmatic hernia in mice and evaluates amniotic fluid stem cell extracellular vesicles as therapy. Results show male predominance in CDH but no sex differences in disease severity or treatment response, with AFSC-EVs improving lung growth, vascularization, and reducing inflammation regardless of biological sex.
Key takeaways
- Male fetuses show higher CDH incidence in this nitrofen model, but pulmonary hypoplasia severity is sex-independent.
- AFSC-EV therapy improves lung growth, vascularization (CD31/eNOS), and reduces inflammation (IL-1β/TNF-α) in CDH lungs.
- Therapeutic response to AFSC-EVs does not differ by fetal sex, suggesting uniform antenatal treatment protocols.
- Ex vivo lung culture with AFSC-EVs demonstrates measurable reversal of CDH-associated pulmonary hypoplasia.
- Extracellular vesicle-based regenerative therapy shows promise for prenatal CDH management regardless of fetal sex.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Sex-specific differences in the severity of pulmonary hypoplasia in experimental congenital diaphragmatic hernia and implications for extracellular vesicle-based therapy. GlobalCastMD Medical Library. 2024-10-28. https://dev.library.globalcastmd.com/article/9355?via_space=staycurrentmd
Comments